[go: up one dir, main page]

CL2007002807A1 - Composicion farmaceutica en estado solido que comprende olanzapina o una sal farmaceuticamente aceptable de la misma y lactosa anhidra; tableta farmaceutica oral; procedimiento de preparacion de dicha tableta, util en el tratamiento de la esquizofren - Google Patents

Composicion farmaceutica en estado solido que comprende olanzapina o una sal farmaceuticamente aceptable de la misma y lactosa anhidra; tableta farmaceutica oral; procedimiento de preparacion de dicha tableta, util en el tratamiento de la esquizofren

Info

Publication number
CL2007002807A1
CL2007002807A1 CL200702807A CL2007002807A CL2007002807A1 CL 2007002807 A1 CL2007002807 A1 CL 2007002807A1 CL 200702807 A CL200702807 A CL 200702807A CL 2007002807 A CL2007002807 A CL 2007002807A CL 2007002807 A1 CL2007002807 A1 CL 2007002807A1
Authority
CL
Chile
Prior art keywords
tablet
anhydra
ski
lactose
procedure
Prior art date
Application number
CL200702807A
Other languages
English (en)
Inventor
Osinga Niels
Original Assignee
Synthon Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthon Bv filed Critical Synthon Bv
Publication of CL2007002807A1 publication Critical patent/CL2007002807A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CL200702807A 2006-09-29 2007-09-28 Composicion farmaceutica en estado solido que comprende olanzapina o una sal farmaceuticamente aceptable de la misma y lactosa anhidra; tableta farmaceutica oral; procedimiento de preparacion de dicha tableta, util en el tratamiento de la esquizofren CL2007002807A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82760706P 2006-09-29 2006-09-29

Publications (1)

Publication Number Publication Date
CL2007002807A1 true CL2007002807A1 (es) 2008-04-11

Family

ID=39182376

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200702807A CL2007002807A1 (es) 2006-09-29 2007-09-28 Composicion farmaceutica en estado solido que comprende olanzapina o una sal farmaceuticamente aceptable de la misma y lactosa anhidra; tableta farmaceutica oral; procedimiento de preparacion de dicha tableta, util en el tratamiento de la esquizofren

Country Status (4)

Country Link
US (1) US20080138409A1 (es)
AR (1) AR063043A1 (es)
CL (1) CL2007002807A1 (es)
WO (1) WO2008037502A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012014012A1 (es) * 2010-07-27 2012-02-02 Laboratorios Andrómaco S.A. Procedimiento para preparar comprimidos de disolucion rapida oral que comprenden la forma i de olanzapina, los comprimidos obtenidos y su uso para el tratamiento de la esquizofrenia.
WO2012153347A2 (en) * 2011-05-04 2012-11-15 Zentiva K.S. Oral pharmaceutical composition of olanzapine form 1
JP2014218472A (ja) * 2013-05-10 2014-11-20 エルメッド エーザイ株式会社 オランザピン乃至その塩含有錠剤

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2212281C3 (de) * 1972-03-14 1978-11-18 Hag Ag Verfahren zur entcoffeinierung von rohkaffee
US4115568A (en) * 1974-11-26 1978-09-19 Lilly Industries Limited Thieno[3,2-b]-[1,5]benzodiazepines
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds
US5605897A (en) * 1991-04-23 1997-02-25 Eli Lilly And Company 2-methyl-thieno-benzodiazepine
GB9313650D0 (en) * 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use
GB9423511D0 (en) * 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
CR5278A (es) * 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
TR199900651T2 (xx) * 1996-09-24 1999-07-21 Eli Lilly And Company Kaplanm�� par�ac�k form�lasyonu.
GB9622173D0 (en) * 1996-10-24 1996-12-18 Glaxo Group Ltd Particulate Products
US6348458B1 (en) * 1999-12-28 2002-02-19 U & I Pharmaceuticals Ltd. Polymorphic forms of olanzapine
US6740753B2 (en) * 2001-01-04 2004-05-25 Geneva Pharmaceuticals, Inc. Olanzapine crystal modification
SI21303A (sl) * 2002-10-18 2004-04-30 Krka, Tovarna Zdravil, D.D.,, Novo Mesto Farmacevtska formulacija olanzapina
US20040265375A1 (en) * 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets
WO2005009407A2 (en) * 2003-07-29 2005-02-03 Ranbaxy Laboratories Limited Oral pharmaceutical formulations of olanzapine
WO2005070938A1 (en) * 2004-01-27 2005-08-04 Synthon B.V. Stable salts of olanzapine
US20050272720A1 (en) * 2004-01-27 2005-12-08 Rolf Keltjens Process for making olanzapine Form I
CZ200563A3 (cs) * 2005-02-02 2006-10-11 Zentiva, A. S. Lécivý prípravek obsahující jako úcinnou slozku olanzapin a zpusob jeho výroby
US20070021605A1 (en) * 2005-07-20 2007-01-25 Rolf Keltjens Process and composition for making olanzapine form i
EP1919923A1 (en) * 2005-08-17 2008-05-14 Synthon B.V. A process for making olanzapine form i
GB0522473D0 (en) * 2005-11-03 2005-12-14 Actavis Group A pharmaceutical formulation
GB0522474D0 (en) * 2005-11-03 2005-12-14 Actavis Group A pharmaceutical formulation
US20070293479A1 (en) * 2006-05-18 2007-12-20 Osinga Niels J Olanzapine pharmaceutical composition
US20080004260A1 (en) * 2006-06-29 2008-01-03 Transcept Pharmaceuticals, Inc. Compositions of 5-HT3 antagonists and dopamine D2 antagonists for treatment of dopamine-associated chronic conditions

Also Published As

Publication number Publication date
AR063043A1 (es) 2008-12-23
WO2008037502A3 (en) 2008-05-22
US20080138409A1 (en) 2008-06-12
WO2008037502A2 (en) 2008-04-03

Similar Documents

Publication Publication Date Title
LT2046298T (lt) Farmacinė vaisto forma, turinti farmaciniu požiūriu priimtiną soliubilizuojančią kompoziciją
PT1827396T (pt) Medicamento oral de libertação modificada de pelo menos um princípio ativo sob forma multimicrocapsular
WO2009081174A3 (en) Anti - retroviral combination
IL196854A (en) Indole compounds and their appropriate pharmaceutical salts and their use in the preparation of @ drugs
AP2012006231A0 (en) Capsule formulation of pirfenidone and pharmaceutically acceptable excipients.
BRPI0812738A2 (pt) Composto, sal farmceuticamente aceitável, composição farmacêutica, uso de um composto, e, método par ao tratamento de uma infecção viral em um humano
EP1940361A4 (en) PHARMACEUTICAL DOSAGE FORMS HAVING CONTROLLED AND / OR IMMEDIATE RELEASE PROPERTIES
GB0412753D0 (en) Pharmaceutical compositions for the treatment of disease and/or symptoms in arthritis
IL195931A0 (en) Pharmaceutical preparation for oral administration with controlled active ingredient release in the small intestine and methods for its production
PT2364983E (pt) Novo derivado tricíclico ou seus sais farmaceuticamente aceitáveis, seu método de preparação, e composição farmacêutica que o contém
ZA200900423B (en) Methods and medicaments for administration of ibuprofen
NO20085302L (no) Farmasoytisk preparat omfattende Amlodipin og Losartan
BRPI0816255A2 (pt) Produto farmacêutico, uso do produto, método para a profilaxia ou o tratamento de doenças, e, composição farmaceuticamente aceitável
IL197575A (en) A method for removing adult stem cells from the blood, using them to prepare drugs for the treatment of lesions, and a medical preparation containing these adult GES cells
CL2007002921A1 (es) Forma solida de dosificacion farmaceutica de administracion oral, que comprende una forma cristalina o amorfa de un compuesto microincluido en un polimero ionico insoluble en agua en proporcion 5:1 a 1:5; y metodo de preparacion.
IL202111A0 (en) Formulations for the oral administration of therapeutic agents and related methods
ATE505203T1 (de) Pharmazeutische kombination aus aliskiren und valsartan
ZA200805761B (en) Pharmaceutical composition for the treatment of nail disease
ZA200701443B (en) Pharmaceutical composition in the form of a gastric-resident tablet containing an active principle
IL191289A (en) Pharmaceuticals containing metitrone and benzodiazepine and their use in the preparation of a drug for the treatment of neuropsychiatric disorders
EP1745793A4 (en) ADSORBENS FOR ORAL ADMINISTRATION; MEANS FOR THE PREVENTION OR TREATMENT OF KIDNEY DISORDERS AND MEANS FOR THE PREVENTION OR TREATMENT OF LIVER DISEASES
CL2007002807A1 (es) Composicion farmaceutica en estado solido que comprende olanzapina o una sal farmaceuticamente aceptable de la misma y lactosa anhidra; tableta farmaceutica oral; procedimiento de preparacion de dicha tableta, util en el tratamiento de la esquizofren
PL385455A1 (pl) Doustna rozpadająca się farmaceutyczna tabletka preparatów olanzapiny
WO2010033954A3 (en) Fixed dose combination in form of a bilayered or monolayered tablet of aliskiren and amlodipine
EP1855647A4 (en) DELAYED RELEASE PHARMACEUTICAL ORAL DOSAGE FORM AND METHOD OF MANUFACTURING THE SAME